NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

Again hiding behind a buffer to do something counterproductive does not shift responsibility for the act, good or bad. A loophole is always policy that’s why it’s a loophole and not a breach of the rules.

So to be clear:

If May 10, 2022 had gone well, would anyone have credibly been able to argue that NWBO did not get the credit when our share price rocketed up?

No. The same arguments defending the company would have been that NWBO cleverly worked around the embargo to put an end to the TLD delay without sacrificing the article.

At no point, in a positive outcome scenario would anyone reasonably argue that NWBO had no responsibility for NYAS, that the release was not done with their approval and therefore responsibility.